Symbols / KTTA
KTTA Chart
About
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 20.02M |
| Enterprise Value | 2.33M | Income | -13.49M | Sales | — |
| Book/sh | 1.64 | Cash/sh | 0.55 | Dividend Yield | — |
| Payout | 0.00% | Employees | 4 | IPO | — |
| P/E | — | Forward P/E | -1.27 | PEG | — |
| P/S | — | P/B | 0.53 | P/C | — |
| EV/EBITDA | -0.18 | EV/Sales | — | Quick Ratio | 2.99 |
| Current Ratio | 4.01 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -4.43 | EPS next Y | -0.68 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2023-08-11 17:00 | ROA | -53.70% |
| ROE | -89.90% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 23.09M |
| Shs Float | 5.29M | Short Float | 1.17% | Short Ratio | 1.13 |
| Short Interest | — | 52W High | 3.79 | 52W Low | 0.28 |
| Beta | 0.21 | Avg Volume | 7.26M | Volume | 82.35K |
| Target Price | $3.00 | Recom | None | Prev Close | $0.83 |
| Price | $0.87 | Change | 4.96% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$3.00
Mean price target
2. Current target
$0.87
Latest analyst target
3. DCF / Fair value
$-6.19
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.87
Low
$3.00
High
$3.00
Mean
$3.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-12-08 | init | HC Wainwright & Co. | — → Buy | $3 |
- NF1-PN drug developer Pasithea to present at Oppenheimer event - Stock Titan ue, 17 Feb 2026 12
- Pasithea Therapeutics Reaches US$104m Market Cap Benefiting Insider Stock Buying - simplywall.st hu, 04 Dec 2025 08
- Pasithea Therapeutics Stock (KTTA) Opinions on PAS-004 Drug Updates - Quiver Quantitative Mon, 01 Dec 2025 08
- Pasithea Therapeutics Receives Nasdaq Minimum Bid Price Notice - TipRanks Fri, 20 Feb 2026 22
- Why Did KTTA Stock Soar A Whopping 43% Today? - Stocktwits Fri, 28 Nov 2025 08
- Pasithea Therapeutics stock plunges after Phase 1 interim data release - Investing.com hu, 20 Nov 2025 08
- Pasithea Therapeutics Corp. (KTTA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade Wed, 19 Nov 2025 13
- HC Wainwright & Co. Initiates Coverage of Pasithea Therapeutics (KTTA) with Buy Recommendation - Nasdaq Mon, 08 Dec 2025 08
- Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock - Yahoo Finance ue, 02 Dec 2025 08
- Pasithea Therapeutics (Nasdaq: KTTA) prices 80M shares at $0.75, extending cash runway through 1H 2028 - Stock Titan Fri, 28 Nov 2025 08
- $KTTA stock is down 16% today. Here's what we see in our data. - Quiver Quantitative Mon, 01 Dec 2025 08
- Pasithea Therapeutics Prices $60 Mln Public Offering To Advance MEK Inhibitor, Stock Up - Nasdaq Fri, 28 Nov 2025 08
- Dumesnil Simon buys Pasithea Therapeutics (KTTA) shares - Investing.com Mon, 01 Dec 2025 08
- Pasithea’s Stock Surge: Is It Time to Invest? - StocksToTrade Fri, 28 Nov 2025 08
- Pasithea Therapeutics (Nasdaq: KTTA) Reports PAS-004 Data With 80% pERK Inhibition - Stock Titan Mon, 24 Nov 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 26667 | 39200 | — | Stock Award(Grant) at price 1.47 per share. | SCHNEIDERMAN DANIEL H | Chief Financial Officer | — | 2025-11-28 00:00:00 | D |
| 1 | 133333 | 196000 | — | Purchase at price 1.47 per share. | STEINMAN LAWRENCE | Director | — | 2025-11-28 00:00:00 | D |
| 2 | 33333 | 49000 | — | Purchase at price 1.47 per share. | MARQUES TIAGO REIS | Chief Executive Officer | — | 2025-11-28 00:00:00 | D |
| 3 | 33333 | 49000 | — | Purchase at price 1.47 per share. | DUMESNIL SIMON | Director | — | 2025-11-28 00:00:00 | D |
| 4 | 33333 | 49000 | — | Stock Award(Grant) at price 1.47 per share. | LEAHY EMER | Director | — | 2025-11-28 00:00:00 | D |
| 5 | 960 | 792 | — | Sale at price 0.82 per share. | MARQUES TIAGO REIS | Chief Executive Officer | — | 2025-05-12 00:00:00 | D |
| 6 | 3500 | 19662 | — | Stock Award(Grant) at price 5.61 - 5.62 per share. | NOVAK ALFRED J | Director | — | 2024-06-13 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -13.52M | -15.39M | -13.43M | -4.51M |
| TotalUnusualItems | -77.81K | 56.24K | 850.45K | 2.33M |
| TotalUnusualItemsExcludingGoodwill | -77.81K | 56.24K | 850.45K | 2.33M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -13.90M | -15.51M | -11.73M | -2.17M |
| ReconciledDepreciation | 649.03K | 648.45K | 5.09K | 1.38K |
| ReconciledCostOfRevenue | 113.19K | 17.27K | ||
| EBITDA | -13.60M | -15.33M | -12.58M | -2.17M |
| EBIT | -14.25M | -15.98M | -12.59M | -2.17M |
| NetInterestIncome | 423.18K | 415.37K | 0.00 | -508.00 |
| InterestExpense | 102.00 | 508.00 | ||
| InterestIncome | 423.18K | 415.37K | 0.00 | |
| NormalizedIncome | -13.83M | -15.56M | -12.58M | -4.51M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -13.90M | -15.96M | -13.94M | -2.17M |
| TotalExpenses | 14.25M | 15.98M | 12.59M | 4.52M |
| TotalOperatingIncomeAsReported | -14.25M | -15.98M | -12.59M | -4.51M |
| DilutedAverageShares | 1.10M | 1.23M | 1.26M | 520.23K |
| BasicAverageShares | 1.10M | 1.23M | 1.26M | 520.23K |
| DilutedEPS | -12.69 | -13.01 | -11.03 | -4.20 |
| BasicEPS | -12.69 | -13.01 | -11.03 | -4.20 |
| DilutedNIAvailtoComStockholders | -13.90M | -15.96M | -13.94M | -2.17M |
| NetIncomeCommonStockholders | -13.90M | -15.96M | -13.94M | -2.17M |
| NetIncome | -13.90M | -15.96M | -13.94M | -2.17M |
| NetIncomeIncludingNoncontrollingInterests | -13.90M | -15.96M | -13.94M | -2.17M |
| NetIncomeDiscontinuousOperations | 0.00 | -453.91K | -2.21M | |
| NetIncomeContinuousOperations | -13.90M | -15.51M | -11.73M | -2.17M |
| TaxProvision | 0.00 | 0.00 | 0.00 | 0.00 |
| PretaxIncome | -13.90M | -15.51M | -11.73M | -2.17M |
| OtherIncomeExpense | -77.81K | 56.24K | 861.09K | 2.33M |
| OtherNonOperatingIncomeExpenses | 10.63K | |||
| SpecialIncomeCharges | 0.00 | -1.00M | 0.00 | |
| OtherSpecialCharges | 1.00M | |||
| GainOnSaleOfSecurity | -77.81K | 56.24K | 1.85M | 2.33M |
| NetNonOperatingInterestIncomeExpense | 423.18K | 415.37K | 0.00 | -508.00 |
| InterestExpenseNonOperating | 102.00 | 508.00 | ||
| InterestIncomeNonOperating | 423.18K | 415.37K | 0.00 | |
| OperatingIncome | -14.25M | -15.98M | -12.59M | -4.51M |
| OperatingExpense | 14.25M | 15.98M | 12.59M | 4.51M |
| ResearchAndDevelopment | 7.20M | 8.10M | 2.67M | 0.00 |
| SellingGeneralAndAdministration | 7.05M | 7.88M | 9.92M | 4.51M |
| GeneralAndAdministrativeExpense | 7.05M | 7.88M | 9.92M | |
| OtherGandA | 7.05M | 7.88M | 9.92M | |
| GrossProfit | 373.36K | -2.21K | ||
| CostOfRevenue | 113.19K | 17.27K | ||
| TotalRevenue | 0.00 | 0.00 | 0.00 | 15.06K |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 15.06K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 1.39M | 1.04M | 1.30M | 1.15M |
| ShareIssued | 1.39M | 1.04M | 1.30M | 1.15M |
| TotalDebt | 0.00 | 81.68K | 504.38K | 0.00 |
| TangibleBookValue | 6.21M | 14.19M | 32.66M | 51.42M |
| InvestedCapital | 14.78M | 23.40M | 42.50M | 51.42M |
| WorkingCapital | 6.25M | 14.06M | 32.20M | 52.85M |
| NetTangibleAssets | 6.21M | 14.19M | 32.66M | 51.42M |
| CapitalLeaseObligations | 0.00 | 81.68K | 504.38K | 0.00 |
| CommonStockEquity | 14.78M | 23.40M | 42.50M | 51.42M |
| TotalCapitalization | 14.78M | 23.40M | 42.50M | 51.42M |
| TotalEquityGrossMinorityInterest | 14.78M | 23.40M | 42.50M | 51.42M |
| StockholdersEquity | 14.78M | 23.40M | 42.50M | 51.42M |
| GainsLossesNotAffectingRetainedEarnings | -7.17K | -4.65K | -661.00 | -10.56K |
| OtherEquityAdjustments | -7.17K | -4.65K | -661.00 | -10.56K |
| RetainedEarnings | -49.58M | -35.32M | -19.36M | -2.21M |
| AdditionalPaidInCapital | 64.37M | 58.72M | 61.86M | 53.63M |
| CapitalStock | 139.00 | 104.00 | 130.00 | 17.68K |
| CommonStock | 139.00 | 104.00 | 130.00 | 17.68K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 1.28M | 2.72M | 2.68M | 1.90M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 162.17K | 84.37K | 804.21K | 1.45M |
| LiabilitiesHeldforSaleNonCurrent | 0.00 | 319.57K | ||
| DerivativeProductLiabilities | 162.17K | 84.37K | 140.61K | 1.45M |
| LongTermDebtAndCapitalLeaseObligation | 0.00 | 344.02K | 0.00 | |
| LongTermCapitalLeaseObligation | 0.00 | 344.02K | 0.00 | |
| CurrentLiabilities | 1.12M | 2.63M | 1.88M | 447.28K |
| OtherCurrentLiabilities | 235.88K | |||
| CurrentDebtAndCapitalLeaseObligation | 81.68K | 160.36K | ||
| CurrentCapitalLeaseObligation | 0.00 | 81.68K | 160.36K | 0.00 |
| PayablesAndAccruedExpenses | 1.12M | 2.55M | 1.48M | 447.28K |
| TotalAssets | 16.06M | 26.12M | 45.18M | 53.32M |
| TotalNonCurrentAssets | 8.70M | 9.42M | 11.10M | 20.12K |
| OtherNonCurrentAssets | 643.38K | |||
| GoodwillAndOtherIntangibleAssets | 8.57M | 9.20M | 9.83M | 0.00 |
| OtherIntangibleAssets | 7.31M | 7.94M | 8.57M | |
| Goodwill | 1.26M | 1.26M | 1.26M | 0.00 |
| NetPPE | 122.34K | 220.48K | 625.62K | 20.12K |
| AccumulatedDepreciation | -42.35K | -23.49K | -3.56K | -1.38K |
| GrossPPE | 164.70K | 243.97K | 629.18K | 21.50K |
| Leases | 3.19K | 3.19K | 3.19K | 0.00 |
| OtherProperties | 155.36K | 234.63K | 599.65K | |
| MachineryFurnitureEquipment | 6.14K | 6.14K | 26.34K | 21.50K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 7.37M | 16.69M | 34.08M | 53.30M |
| OtherCurrentAssets | 142.94K | 104.71K | 262.99K | |
| AssetsHeldForSaleCurrent | 0.00 | 163.46K | ||
| PrepaidAssets | 302.64K | 215.90K | 562.38K | 333.75K |
| Receivables | 0.00 | 40.50K | 0.00 | 0.00 |
| OtherReceivables | 40.50K | 302.13K | ||
| CashCashEquivalentsAndShortTermInvestments | 6.92M | 16.33M | 33.09M | 52.97M |
| CashAndCashEquivalents | 6.92M | 16.33M | 33.09M | 52.97M |
| CashEquivalents | 6.10M | 13.40M | ||
| CashFinancial | 822.73K | 2.93M | 33.15M | 52.97M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -13.92M | -13.46M | -13.80M | -3.20M |
| RepurchaseOfCapitalStock | 0.00 | -3.73M | -3.21M | 0.00 |
| RepaymentOfDebt | 0.00 | -392.35K | 0.00 | |
| IssuanceOfDebt | 0.00 | 392.35K | 0.00 | |
| IssuanceOfCapitalStock | 0.00 | 50.24M | ||
| CapitalExpenditure | -34.30K | -107.10K | -21.50K | |
| EndCashPosition | 6.92M | 16.33M | 33.09M | 52.97M |
| BeginningCashPosition | 16.33M | 33.09M | 52.90M | 243.65K |
| EffectOfExchangeRateChanges | -2.52K | -3.99K | 9.90K | -10.56K |
| ChangesInCash | -9.41M | -16.75M | -19.82M | 52.73M |
| FinancingCashFlow | 4.52M | -3.73M | -3.21M | 55.93M |
| CashFromDiscontinuedFinancingActivities | 0.00 | 0.00 | 0.00 | |
| CashFlowFromContinuingFinancingActivities | 4.52M | -3.73M | -3.21M | 55.93M |
| NetOtherFinancingCharges | -481.50K | -1.31M | ||
| ProceedsFromStockOptionExercised | 5.00M | 0.00 | 0.00 | 7.00M |
| NetCommonStockIssuance | 0.00 | -3.73M | -3.21M | 50.24M |
| CommonStockPayments | 0.00 | -3.73M | -3.21M | 0.00 |
| CommonStockIssuance | 0.00 | 50.24M | ||
| NetIssuancePaymentsOfDebt | 0.00 | 0.00 | 0.00 | |
| NetLongTermDebtIssuance | 0.00 | 0.00 | 0.00 | |
| LongTermDebtPayments | 0.00 | -392.35K | 0.00 | |
| LongTermDebtIssuance | 0.00 | 392.35K | 0.00 | |
| InvestingCashFlow | 0.00 | 399.01K | -2.93M | -21.50K |
| CashFromDiscontinuedInvestingActivities | 0.00 | 323.81K | -626.90K | |
| CashFlowFromContinuingInvestingActivities | 0.00 | 75.20K | -2.30M | -21.50K |
| NetOtherInvestingChanges | 109.50K | |||
| NetBusinessPurchaseAndSale | 0.00 | -2.19M | 0.00 | |
| SaleOfBusiness | 77.06K | 0.00 | ||
| PurchaseOfBusiness | 0.00 | -2.19M | ||
| NetIntangiblesPurchaseAndSale | -1.76M | 0.00 | ||
| PurchaseOfIntangibles | -1.76M | 0.00 | ||
| NetPPEPurchaseAndSale | 0.00 | -34.30K | -107.10K | -21.50K |
| PurchaseOfPPE | 0.00 | -34.30K | -107.10K | -21.50K |
| OperatingCashFlow | -13.92M | -13.43M | -13.69M | -3.17M |
| CashFromDiscontinuedOperatingActivities | 0.00 | -611.28K | -1.80M | |
| CashFlowFromContinuingOperatingActivities | -13.92M | -12.81M | -11.89M | -3.17M |
| ChangeInWorkingCapital | -1.52M | 1.57M | 845.35K | 111.23K |
| ChangeInOtherCurrentLiabilities | -2.41K | -1.55K | 543.96K | |
| ChangeInOtherCurrentAssets | 2.26K | 158.28K | -262.99K | 0.00 |
| ChangeInPayablesAndAccruedExpense | -1.43M | 1.07M | 745.76K | 440.68K |
| ChangeInPrepaidAssets | -86.75K | 346.48K | -181.37K | -329.44K |
| OtherNonCashItems | 356.55K | 750.00K | ||
| StockBasedCompensation | 773.69K | 592.27K | 835.06K | 471.25K |
| AssetImpairmentCharge | 423.41K | 0.00 | ||
| DepreciationAmortizationDepletion | 649.03K | 648.45K | 5.09K | 1.38K |
| DepreciationAndAmortization | 649.03K | 648.45K | 5.09K | 1.38K |
| AmortizationCashFlow | 630.16K | 630.16K | 0.00 | 0.00 |
| AmortizationOfIntangibles | 630.16K | 630.16K | 0.00 | 0.00 |
| Depreciation | 18.86K | 18.29K | 5.09K | 1.38K |
| OperatingGainsLosses | 77.81K | -121.29K | -1.85M | -2.33M |
| GainLossOnInvestmentSecurities | 77.81K | -56.24K | -1.85M | -2.33M |
| NetIncomeFromContinuingOperations | -13.90M | -15.51M | -11.73M | -2.17M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for KTTA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|